Michael Singer - 13 Nov 2023 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: RNAC
Reported as of: 13 Nov 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Nov 2023, 16:41:44 UTC
Next SEC filing: 04 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Michael Singer

Key filing fact

Michael Singer filed Form 4 for Cartesian Therapeutics, Inc. (RNAC) on 15 Nov 2023.

Key facts

This page summarizes Michael Singer's Form 4 filing for Cartesian Therapeutics, Inc. (RNAC).
14 reported transactions and 7 derivative rows are listed below.
Accepted by SEC: 15 Nov 2023, 16:41.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SELB transaction

Common Stock

Award

Transaction value: $0
Shares: +110,123
Change %
Price: $0.000000
Shares after: 110,123
Date: 13 Nov 2023
Ownership: Direct
Footnotes: F1

SELB transaction

Common Stock

Other

Transaction value: $0
Shares: +197,663
Change %
Price: $0.000000
Shares after: 197,663
Date: 13 Nov 2023
Ownership: by trust
Footnotes: F1, F2

SELB transaction

Common Stock

Other

Transaction value: $0
Shares: +29,212
Change %
Price: $0.000000
Shares after: 29,212
Date: 13 Nov 2023
Ownership: by trust
Footnotes: F1, F3

SELB transaction

Common Stock

Other

Transaction value: $0
Shares: +3,670
Change %
Price: $0.000000
Shares after: 3,670
Date: 13 Nov 2023
Ownership: by trust
Footnotes: F1, F4

SELB transaction

Common Stock

Other

Transaction value: $0
Shares: +49,555
Change %
Price: $0.000000
Shares after: 49,555
Date: 13 Nov 2023
Ownership: as custodian
Footnotes: F1, F5

SELB transaction

Common Stock

Other

Transaction value: $0
Shares: +49,555
Change %
Price: $0.000000
Shares after: 49,555
Date: 13 Nov 2023
Ownership: as custodian
Footnotes: F1, F6

SELB transaction

Common Stock

Other

Transaction value: $0
Shares: +7,616
Change %
Price: $0.000000
Shares after: 7,616
Date: 13 Nov 2023
Ownership: by spouse
Footnotes: F1, F7

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SELB transaction Derivative

Series A Non-Voting Convertible Preferred Stock

Award

Transaction value
Shares: +6,305
Change %
Price
Shares after: 6,305
Date: 13 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,304,559
Exercise price
Footnotes: F1, F8

SELB transaction Derivative

Series A Non-Voting Convertible Preferred Stock

Other

Transaction value
Shares: +11,316
Change %
Price
Shares after: 11,316
Date: 13 Nov 2023
Ownership: by trust
Underlying class: Common Stock
Underlying amount: 11,316,263
Exercise price
Footnotes: F1, F2, F8

SELB transaction Derivative

Series A Non-Voting Convertible Preferred Stock

Other

Transaction value
Shares: +1,672
Change %
Price
Shares after: 1,672
Date: 13 Nov 2023
Ownership: by trust
Underlying class: Common Stock
Underlying amount: 1,672,389
Exercise price
Footnotes: F1, F3, F8

SELB transaction Derivative

Series A Non-Voting Convertible Preferred Stock

Other

Transaction value
Shares: +210
Change %
Price
Shares after: 210
Date: 13 Nov 2023
Ownership: by trust
Underlying class: Common Stock
Underlying amount: 210,152
Exercise price
Footnotes: F1, F4, F8

SELB transaction Derivative

Series A Non-Voting Convertible Preferred Stock

Other

Transaction value
Shares: +2,837
Change %
Price
Shares after: 2,837
Date: 13 Nov 2023
Ownership: as custodian
Underlying class: Common Stock
Underlying amount: 2,837,052
Exercise price
Footnotes: F1, F5, F8

SELB transaction Derivative

Series A Non-Voting Convertible Preferred Stock

Other

Transaction value
Shares: +2,837
Change %
Price
Shares after: 2,837
Date: 13 Nov 2023
Ownership: as custodian
Underlying class: Common Stock
Underlying amount: 2,837,052
Exercise price
Footnotes: F1, F6, F8

SELB transaction Derivative

Series A Non-Voting Convertible Preferred Stock

Other

Transaction value
Shares: +436
Change %
Price
Shares after: 436
Date: 13 Nov 2023
Ownership: by spouse
Underlying class: Common Stock
Underlying amount: 436,066
Exercise price
Footnotes: F1, F7, F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 8 footnotes

Footnote F1

On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger.

Footnote F2

Shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the trust.

Footnote F3

Shares are held in a trust for which the reporting person is a beneficiary. The reporting person is a trustee of the trust.

Footnote F4

Shares are held in a trust for which the reporting person is a beneficiary. The reporting person's spouse is a trustee of the trust.

Footnote F5

The shares are held for LS, the child of the reporting person, through a custodial account established pursuant to the Uniform Transfer to Minors Act ("UTMA") for which the reporting person serves as custodian.

Footnote F6

The shares are held for SS, the child of the reporting person, through a custodial account established pursuant to the UTMA for which the reporting person serves as custodian.

Footnote F7

Shares are held by the reporting person's spouse.

Footnote F8

Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.